Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...
Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...
Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...
When treating mild allergic reactions, allergists and pediatricians prefer children’s Zyrtec over children’s Benadryl. OTC ...
Honey bees symmetrically organize nest contents, benefiting brood development and temperature control, consistent across species. Symmetry is everywhere and serves a myriad of purposes. Humans find ...
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...
We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...